Literature DB >> 20197625

Loss of the BMP antagonist USAG-1 ameliorates disease in a mouse model of the progressive hereditary kidney disease Alport syndrome.

Mari Tanaka1, Misako Asada, Atsuko Y Higashi, Jin Nakamura, Akiko Oguchi, Mayumi Tomita, Sachiko Yamada, Nariaki Asada, Masayuki Takase, Tomohiko Okuda, Hiroshi Kawachi, Aris N Economides, Elizabeth Robertson, Satoru Takahashi, Takeshi Sakurai, Roel Goldschmeding, Eri Muso, Atsushi Fukatsu, Toru Kita, Motoko Yanagita.   

Abstract

The glomerular basement membrane (GBM) is a key component of the filtering unit in the kidney. Mutations involving any of the collagen IV genes (COL4A3, COL4A4, and COL4A5) affect GBM assembly and cause Alport syndrome, a progressive hereditary kidney disease with no definitive therapy. Previously, we have demonstrated that the bone morphogenetic protein (BMP) antagonist uterine sensitization-associated gene-1 (USAG-1) negatively regulates the renoprotective action of BMP-7 in a mouse model of tubular injury during acute renal failure. Here, we investigated the role of USAG-1 in renal function in Col4a3-/- mice, which model Alport syndrome. Ablation of Usag1 in Col4a3-/- mice led to substantial attenuation of disease progression, normalization of GBM ultrastructure, preservation of renal function, and extension of life span. Immunohistochemical analysis revealed that USAG-1 and BMP-7 colocalized in the macula densa in the distal tubules, lying in direct contact with glomerular mesangial cells. Furthermore, in cultured mesangial cells, BMP-7 attenuated and USAG-1 enhanced the expression of MMP-12, a protease that may contribute to GBM degradation. These data suggest that the pathogenetic role of USAG-1 in Col4a3-/- mice might involve crosstalk between kidney tubules and the glomerulus and that inhibition of USAG-1 may be a promising therapeutic approach for the treatment of Alport syndrome.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20197625      PMCID: PMC2827946          DOI: 10.1172/JCI39569

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  70 in total

Review 1.  Alport's syndrome, Goodpasture's syndrome, and type IV collagen.

Authors:  Billy G Hudson; Karl Tryggvason; Munirathinam Sundaramoorthy; Eric G Neilson
Journal:  N Engl J Med       Date:  2003-06-19       Impact factor: 91.245

Review 2.  Genetics of rare diseases of the kidney: learning from mouse models.

Authors:  C Zoja; M Morigi; A Benigni; G Remuzzi
Journal:  Cytogenet Genome Res       Date:  2004       Impact factor: 1.636

Review 3.  Anatomy of the juxtaglomerular apparatus.

Authors:  L Barajas
Journal:  Am J Physiol       Date:  1979-11

4.  Distal tubular feedback control of renal hemodynamics and autoregulation.

Authors:  L G Navar; D W Ploth; P D Bell
Journal:  Annu Rev Physiol       Date:  1980       Impact factor: 19.318

5.  Bone morphogenic protein-7 inhibits progression of chronic renal fibrosis associated with two genetic mouse models.

Authors:  Michael Zeisberg; Cindy Bottiglio; Navin Kumar; Yohei Maeshima; Frank Strutz; Gerhard A Müller; Raghu Kalluri
Journal:  Am J Physiol Renal Physiol       Date:  2003-08-12

Review 6.  Kidney-bone, bone-kidney, and cell-cell communications in renal osteodystrophy.

Authors:  Keith A Hruska; Georges Saab; Lala R Chaudhary; Cheryl O Quinn; Richard J Lund; Kameswaran Surendran
Journal:  Semin Nephrol       Date:  2004-01       Impact factor: 5.299

Review 7.  Basement membranes: structure, assembly and role in tumour angiogenesis.

Authors:  Raghu Kalluri
Journal:  Nat Rev Cancer       Date:  2003-06       Impact factor: 60.716

8.  USAG-1: a bone morphogenetic protein antagonist abundantly expressed in the kidney.

Authors:  Motoko Yanagita; Masako Oka; Tetsuro Watabe; Haruhisa Iguchi; Atsushi Niida; Satoru Takahashi; Tetsu Akiyama; Kohei Miyazono; Masashi Yanagisawa; Takeshi Sakurai
Journal:  Biochem Biophys Res Commun       Date:  2004-04-02       Impact factor: 3.575

9.  Activin receptor-like kinase (ALK)1 is an antagonistic mediator of lateral TGFbeta/ALK5 signaling.

Authors:  Marie José Goumans; Gudrun Valdimarsdottir; Susumu Itoh; Franck Lebrin; Jonas Larsson; Christine Mummery; Stefan Karlsson; Peter ten Dijke
Journal:  Mol Cell       Date:  2003-10       Impact factor: 17.970

10.  BMP-7 counteracts TGF-beta1-induced epithelial-to-mesenchymal transition and reverses chronic renal injury.

Authors:  Michael Zeisberg; Jun-ichi Hanai; Hikaru Sugimoto; Tadanori Mammoto; David Charytan; Frank Strutz; Raghu Kalluri
Journal:  Nat Med       Date:  2003-07       Impact factor: 53.440

View more
  36 in total

Review 1.  Renal interstitial fibrosis: mechanisms and evaluation.

Authors:  Alton B Farris; Robert B Colvin
Journal:  Curr Opin Nephrol Hypertens       Date:  2012-05       Impact factor: 2.894

2.  The phosphatase Dullard negatively regulates BMP signalling and is essential for nephron maintenance after birth.

Authors:  Masaji Sakaguchi; Sazia Sharmin; Atsuhiro Taguchi; Tomoko Ohmori; Sayoko Fujimura; Takaya Abe; Hiroshi Kiyonari; Yoshihiro Komatsu; Yuji Mishina; Makoto Asashima; Eiichi Araki; Ryuichi Nishinakamura
Journal:  Nat Commun       Date:  2013       Impact factor: 14.919

3.  Angiotensin-converting enzyme 2 amplification limited to the circulation does not protect mice from development of diabetic nephropathy.

Authors:  Jan Wysocki; Minghao Ye; Ahmed M Khattab; Agnes Fogo; Aline Martin; Nicolae Valentin David; Yashpal Kanwar; Mark Osborn; Daniel Batlle
Journal:  Kidney Int       Date:  2016-12-04       Impact factor: 10.612

4.  Distinct bone morphogenetic proteins activate indistinguishable transcriptional responses in nephron epithelia including Notch target genes.

Authors:  Barry W Larman; Michele J Karolak; Volkhard Lindner; Leif Oxburgh
Journal:  Cell Signal       Date:  2011-09-16       Impact factor: 4.315

Review 5.  BMP signaling and its modifiers in kidney development.

Authors:  Ryuichi Nishinakamura; Masaji Sakaguchi
Journal:  Pediatr Nephrol       Date:  2013-11-12       Impact factor: 3.714

6.  Heterogeneous fibroblasts underlie age-dependent tertiary lymphoid tissues in the kidney.

Authors:  Yuki Sato; Akiko Mii; Yoko Hamazaki; Harumi Fujita; Hirosuke Nakata; Kyoko Masuda; Shingo Nishiyama; Shinsuke Shibuya; Hironori Haga; Osamu Ogawa; Akira Shimizu; Shuh Narumiya; Tsuneyasu Kaisho; Makoto Arita; Masashi Yanagisawa; Masayuki Miyasaka; Kumar Sharma; Nagahiro Minato; Hiroshi Kawamoto; Motoko Yanagita
Journal:  JCI Insight       Date:  2016-07-21

Review 7.  Collagen IV diseases: A focus on the glomerular basement membrane in Alport syndrome.

Authors:  Dominic Cosgrove; Shiguang Liu
Journal:  Matrix Biol       Date:  2016-08-27       Impact factor: 11.583

8.  Pentraxin-2 suppresses c-Jun/AP-1 signaling to inhibit progressive fibrotic disease.

Authors:  Naoki Nakagawa; Luke Barron; Ivan G Gomez; Bryce G Johnson; Allie M Roach; Sei Kameoka; Richard M Jack; Mark L Lupher; Sina A Gharib; Jeremy S Duffield
Journal:  JCI Insight       Date:  2016-12-08

Review 9.  An update on the pathomechanisms and future therapies of Alport syndrome.

Authors:  Damien Noone; Christoph Licht
Journal:  Pediatr Nephrol       Date:  2012-08-18       Impact factor: 3.714

10.  Grem2 mediates podocyte apoptosis in high glucose milieu.

Authors:  Hongxiu Wen; Vinod Kumar; Abheepsa Mishra; Su Song; Rukhsana Aslam; Ali Hussain; Haichao Wang; Xiaogang Zhou; Xiaoming He; Guisheng Wu; Huairong Luo; Xiqian Lan; Ashwani Malhotra; Pravin C Singhal
Journal:  Biochimie       Date:  2019-03-01       Impact factor: 4.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.